Evidence map›Paper›PMID 39704853›Full record

ArticleMolecular biology reports2024

A pilot study on the efficacy of a telomerase activator in regulating the proliferation of A375 skin cancer cell line.

M K Makalakshmi, Antara Banerjee, Surajit Pathak, Sujay Paul, Neeta Raj Sharma, B Anandan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Biomolecules · 2026
    Review
  2. Cutaneous Melanoma in the Context of Aging.Medicina (Kaunas, Lithuania) · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M K MakalakshmiMedical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, India.
Antara BanerjeeMedical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, India. antarabanerjee@care.edu.in.ORCID http://orcid.org/0000-0002-5519-6878
Surajit PathakMedical Biotechnology, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Kelambakkam, India. surajit.pathak@gmail.com.
Sujay PaulTecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Querétaro, CP 76130, Mexico.
Neeta Raj SharmaSchool of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India.
B AnandanDepartment of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamilnadu, 600113, India. anand_gem@yahoo.com.

Funding

Chettinad Academy of Research and Education Departmental grants
6 · The paper itself

Abstract

introductionThe changes in histone modifications are linked to the progression of benign and normal tissue to malignancy. Thus, numerous findings suggest that targeting epigenetic factors might be a focus for anti-cancer treatment. In this study, we tested the hypothesis that telomerase activator might be a potential epigenetic regulator in combatting skin cancer cell proliferation.

methodsMelanoma cell line A375 cells were treated with telomerase activator TA-65. Cell senescence assay was done to evaluate the senescence induction. Morphological changes and differences in expression of HDACs and hTERT genes were studied. Further, hyaluronidase and anti-oxidant assays were also performed. Additionally, telomerase enzyme and 20S proteasome activity was also studied.

resultsMorphological changes were observed in treated cells and it is evident that telomerase activator induced cellular senescence in high concentrations. From our results, it is evident that HDAC8 and  HDAC10 expression was upregulated, whereas hTERT gene expression was downregulated in treated groups. This suggests that the telomerase activator has a regulatory role in skin cancer cells proliferation by targeting the epigenetic factors.

conclusionTargeting HDACs and hTERT in the treatment of melanoma is a prominent concern. In our current study, we highlight the most recent research, although in its initial stage, involving various epigenetic factors involved in melanoma cells proliferation.

Indexed as

Cell ProliferationGene Expression Regulation, NeoplasticHistone DeacetylasesMelanomaSkin NeoplasmsTelomeraseCell Line, TumorCellular SenescenceEpigenesis, GeneticHumansPilot ProjectsHistone DeacetylasesTelomeraseTERT protein, humanEpigeneticsHDACsMelanomaSkin ageingTelomerase activatorTelomere

Identifiers

PMID39704853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.